To conclude, plasma p217+tau performs well for detecting persons with brain amyloid and discriminating those with Intermediate or Advanced stages from those at a lower stage, a useful property to reduce the number of tau PET required when screening for individuals at a particular stage of AD. The gene discussed is MAPT; the disease is Alzheimer disease.